The Century Report mRNA Cancer Vaccine Clears Phase 3 - TCR 08/20/26 Moderna and Merck's individualized mRNA melanoma therapy plus Keytruda met both survival endpoints in a 1,137-patient Phase 3, the first win for the class.
